Alternative litigation financing in the United States : issues, knowns, and unknowns / / Steven Garber |
Autore | Garber Steven <1950-> |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Santa Monica, Calif., : RAND, 2010 |
Descrizione fisica | 1 online resource (68 p.) |
Disciplina | 347.73/77 |
Collana | Occasional paper |
Soggetto topico |
Costs (Law) - United States
Practice of law - Economic aspects - United States Lawyers - Fees - United States Law and economics |
ISBN |
1-282-94047-3
9786612940477 0-8330-5072-9 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Introduction -- Overview of this paper -- A snapshot of the U.S. ALF industry, as of early 2010 -- Different meanings of ethics and implications for ALF activity -- Microeconomic perspectives on the current and near-term effects of ALF on litigation -- Policy assessment and the effects of ALF over time -- Concluding comments. |
Record Nr. | UNINA-9910219978903321 |
Garber Steven <1950-> | ||
Santa Monica, Calif., : RAND, 2010 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Redirecting innovation in U.S. health care : options to decrease spending and increase value / / Steven Garber [and six others] |
Autore | Garber Steven <1950-> |
Pubbl/distr/stampa | Santa Monica, California : , : RAND Corporation, , 2014 |
Descrizione fisica | 1 online resource (135 p.) |
Disciplina | 362.10973 |
Soggetto topico |
Medical care - United States
Medical care, Cost of - United States Medical innovations |
ISBN |
0-8330-8549-2
0-8330-8547-6 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Cover; Title Page; Copyright; Preface; Contents; Figures; Summary; Acknowledgments; Abbreviations; Chapter One: Introduction; Project Goals; What Determines Value for Health Care Products?; Chapter Two: The Context for Medical Product Innovation; Three Stages of Innovation; Primary Actors in Inventing Medical Products; Drug and Device Companies; HIT Companies; Goals of Medical Product Inventors; Private Investors; Financial Incentives of Medical Product Inventors; Influencers of Medical Product Invention; National Institutes of Health; U.S. Food and Drug Administration
U.S. Patent and Trademark Office Office of the National Coordinator for Health Information Technology; Primary Actor and Influencers in Approval of Medical Technologies; Primary Actors in Adoption of Medical Products; Physicians; Hospitals; Influencers of Providers; Summary: Context for Medical Product Innovation; Chapter Three: Methods; Literature Reviews; Technical Expert Panel; Expert Interviews; Case Studies; Policy Options; Chapter Four: Analysis; Lack of Basic Scientific Knowledge; Lack of an Adequate Knowledge Base Can Hinder Product Inventors Sources of Financial Support for Increasing Basic Scientific Knowledge Federal Funding Is Critical to Expanding the Basic Scientific Base; Case Study Summary: Haemophilus influenzae Type b (Hib) Vaccine; How Scientific Uncertainty Affects Medical Product Invention; Costs and Risks of FDA Approval; Could the FDA Ensure Safety with Quicker and Less Costly Processes?; Delays Entail Both Health and Financial Costs; Case Study Summary: A Cardiovascular Polypill; Unpredictability and Ineffective Communication Complicate the Approval Process; FDA Caution May Be a Root Cause of Regulatory Delay Case Study Summary: Avastin for Metastatic Breast Cancer Regulatory Risk Figures Prominently in Investment and Invention Decisions; How Regulatory Uncertainty Affects Investment and Invention; Limited Rewards for Medical Products That Could Lower Spending; Many Patients and Providers Are Fairly Insensitive to Prices; Generous Health Insurance Tends to Reduce Consumers' Sensitivity to Price; Fee-for-Service Payment Also Tends to Reduce Price Sensitivity; Lack of Price Transparency Also Reduces Price Sensitivity; Medicare Is Not Allowed to Consider Costs in Coverage and Reimbursement Decisions Limited Time Horizons and Fragmented Decision making Case Study Summary: Electronic Health Records; Inadequate Rewards for Products That Decrease Spending; Implications for Inventors and Investors; Treatment Creep; Case Study Summary: Implantable Cardioverter-Defibrillator; Manufacturers Can Promote Low-Value Use; Case Study Summary: Prostate-Specific Antigen; Defensive Medicine Is a Form of Treatment Creep; Off-Label Use of Medical Products Is Widespread, but Health Effects Are Unknown; It Is Difficult to Control Undesirable Instances of Off-Label Use Treatment Creep Can Substantially Affect Incentives for Innovators |
Record Nr. | UNINA-9910220091803321 |
Garber Steven <1950-> | ||
Santa Monica, California : , : RAND Corporation, , 2014 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|